摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone

中文名称
——
中文别名
——
英文名称
3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone
英文别名
4-[(Z)-[[4-[(dimethylamino)methyl]phenyl]amino](6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-benzenepropanoic acid;3-[4-[(Z)-[4-[(dimethylamino)methyl]anilino]-(6-fluoro-2-oxo-1H-indol-3-ylidene)methyl]phenyl]propanoic acid
3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone化学式
CAS
——
化学式
C27H26FN3O3
mdl
——
分子量
459.52
InChiKey
MXJOFHZXYMJNPZ-QPLCGJKRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.84
  • 重原子数:
    34.0
  • 可旋转键数:
    8.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    81.67
  • 氢给体数:
    3.0
  • 氢受体数:
    4.0

反应信息

  • 作为反应物:
    描述:
    3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone盐酸 作用下, 以 丙酮 为溶剂, 以88.4%的产率得到4-[(Z)-[[4-[(dimethylamino)methyl]phenyl]amino](6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-benzenepropanoic acid monohydrochloride
    参考文献:
    名称:
    [EN] SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    [FR] FORMES DE SEL D'UN DÉRIVÉ DE 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDÈNE, PROCÉDÉ DE FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT
    摘要:
    本发明涉及化合物4-[(Z)-[[4-[(二甲氨基)甲基]苯基]氨基]-氟-1,2-二氢-2-氧-3H-吲哚-3-基亚甲基]-苯丙酸的盐形式,适用于药物开发,并涉及其制备方法。
    公开号:
    WO2009092581A1
  • 作为产物:
    描述:
    3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-ethoxycarbonylethyl)phenyl)methylene]-6-fluoro-2-indolinone 在 、 sodium hydroxide 、 盐酸 作用下, 以 甲醇 为溶剂, 反应 2.0h, 以94.4%的产率得到3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]-6-fluoro-2-indolinone
    参考文献:
    名称:
    [EN] SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    [FR] FORMES DE SEL D'UN DÉRIVÉ DE 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDÈNE, PROCÉDÉ DE FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT
    摘要:
    本发明涉及化合物4-[(Z)-[[4-[(二甲氨基)甲基]苯基]氨基]-氟-1,2-二氢-2-氧-3H-吲哚-3-基亚甲基]-苯丙酸的盐形式,适用于药物开发,并涉及其制备方法。
    公开号:
    WO2009092581A1
点击查看最新优质反应信息

文献信息

  • [EN] COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION<br/>[FR] COMBINAISONS POUR TRAITEMENT DE MALADIES IMPLIQUANT UNE PROLIFÉRATION CELLULAIRE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2006018182A1
    公开(公告)日:2006-02-23
    The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    本发明涉及一种用于治疗涉及细胞增殖的疾病的药物组合物。该发明还涉及一种治疗上述疾病的方法,包括共同给药于一种具有以下式(I)的化合物1,其中基团L、R1、R2、R3、R4和R5具有索赔和规范中给定的含义,可选地以其互变异构体、消旋体、对映体、二对映异构体和它们的混合物的形式,以及可选地以药理学上可接受的酸盐、溶剂化合物、水合物、多型、生理功能衍生物或其前药的形式,以及与有效量的活性化合物2和/或辐射治疗共同治疗,其比例提供加成和协同作用,并且结合使用具有以下式(I)的化合物1和有效量的活性化合物2和/或放射治疗用于制备相应的药物组合制剂。
  • Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments
    申请人:Roth Juergen Gerald
    公开号:US20050043389A1
    公开(公告)日:2005-02-24
    The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R 1 to R 6 and X are as defined in claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.
    本发明涉及6-位取代的吲哚酮衍生物,其化学式为其中R1至R6和X如权利要求1中定义的,以及它们的互变异构体、对映体、顺反异构体、它们的混合物和它们的盐,特别是它们的生理上可接受的盐,具有有用的药理特性,特别是在抑制各种受体酪氨酸激酶的作用和对内皮细胞和各种肿瘤细胞的增殖方面,在包括这些化合物的药物、它们的使用和制备它们的方法方面。
  • Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
    申请人:Heckel Armin
    公开号:US20060194813A1
    公开(公告)日:2006-08-31
    The present invention relates to indolinone derivatives substituted in the 6 position of general formula wherein R 1 to R 6 and X are defined as in claim 1 , the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    本发明涉及一种在通式中6位取代的吲哚酮衍生物,其中R1至R6和X如权利要求1所定义,其互变异构体、对映异构体、顺反异构体、混合物及其盐,特别是其生理上可接受的盐,具有有价值的药理特性,特别是对各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞的增殖具有抑制作用,包含这些化合物的制药组合物,它们的用途和制备过程。
  • Combinations for the treatment of diseases involving cell proliferation
    申请人:Munzert Gerd
    公开号:US20060058311A1
    公开(公告)日:2006-03-16
    Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    本发明涉及用于治疗包括细胞增殖的疾病的药物组合物。本发明还涉及治疗上述疾病的方法,包括联合给予式(I)式中L、R1、R2、R3、R4和R5所表示的基团的化合物1和有效量的活性化合物2和/或放射治疗,其比例提供加成和协同作用,并且联合使用式(I)式中的化合物1和有效量的活性化合物2和/或放射治疗制备相应的药物组合制剂。
  • Combinations for the Treatment of Diseases involving Cell Proliferation
    申请人:MUNZERT Gerd
    公开号:US20090238828A1
    公开(公告)日:2009-09-24
    Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    本发明涉及用于治疗涉及细胞增殖的疾病的药物组合物。本发明还涉及治疗该类疾病的方法,包括共同给予式(I)中化合物1,其中L,R1,R2,R3,R4和R5的基团具有所述的含义,以及有效量的活性化合物2和/或放射治疗的联合治疗,其比例提供加成和协同作用,并且用于制备相应的药物组合制剂的式(I)中化合物1和有效量的活性化合物2和/或放射治疗的联合使用。
查看更多